Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 27, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements executed on March 20 and March 21, 2006, involving the SmithKline Beecham Employee Benefit Trust and various employee investment plans:
- Sale: 782 Ordinary shares sold on behalf of a SmithKline Beecham Bonus Investment Plan participant at GBP 15.37.
- Transfer: 2,567 Ordinary shares transferred from the Trust to a SmithKline Beecham Bonus Investment Plan participant.
- Purchase: 184,233 Ordinary shares purchased on behalf of GlaxoSmithKline Annual Investment Plan participants at GBP 15.46.
- Transfer: 9,175 Ordinary shares transferred from the Trust to a GlaxoSmithKline Annual Investment Plan participant.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Trust is a discretionary fund for non-US employees and former employees, and that Director Mr. J Heslop holds an interest in the fund shares similarly to other beneficiaries.
Investor Verification Points
- Verify the total volume of shares purchased versus sold in the reported period to assess net insider/employee plan activity.
- Confirm the share price range (GBP 15.37 to GBP 15.46) against market prices on March 20-21, 2006.
- Review the specific roles of connected persons involved in the transactions to ensure compliance with Disclosure Rule 3.1.4R (1) (b).